References
- Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305–312
- Zahradnik H P, Wetzka B, Schuth W. Zyklusabhängige Befindlichkeitsstörungen der Frau. Gynäkologe 2000; 33: 225–238
- Ardila M D, Binek M, Mojica C, Sanchez F. Experiences with the new oral contraceptive EE/CMA (ethinyl estradiol/chlormadinone acetate) in Columbia: An observational phase IV study. Abstract from 6th Congress of the European Society of Gynaecology, , et al, Helsinki 2005
- COSS-Study. Clin. Biochem, , et al, Grünenthal, Report 2003
- Worret I, Arp W, Zahradnik H P, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara®) and EE/LNG (Microgynon®). Dermatology 2001; 203: 38–44
- Zahradnik H P, Goldberg J, Andreas J -O. Efficacy and safety of the new anti-androgenic oral contraceptive Belara®. Contraception 1998; 57: 103–109